Addex Therapeutics Ltd (ADXN)
7.65
-0.15 (-1.92%)
At close: Jan 14, 2025, 3:54 PM
7.74
1.18%
Pre-market Jan 15, 2025, 04:03 AM EST
undefined% (undefined)
| Bid | 7.77 |
| Market Cap | 11.94M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -20.94 |
| PE Ratio (ttm) | -0.37 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 12.38 |
| Volume | 74,605 |
| Avg. Volume (20D) | 41,562 |
| Open | 7.96 |
| Previous Close | 7.80 |
| Day's Range | 7.45 - 8.35 |
| 52-Week Range | 6.45 - 27.90 |
| Beta | undefined |
About ADXN
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX7...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 12, 2020
Employees 23
Stock Exchange NASDAQ
Ticker Symbol ADXN
Analyst Forecast
According to 1 analyst ratings, the average rating for ADXN stock is "Buy." The 12-month stock price forecast is $30, which is an increase of 292.16% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago ·
Source
-18.65%
Addex Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
3 months ago ·
Source
+7.96%
Addex Therapeutics shares are trading higher after the company reported H2 financial results.
